Research reveals Pfizer-BioNTech COVID-19 vaccine elicits strong immune response with single dose
The response among those previously infected was so effective that it opens the debate as to whether one dose of the vaccine may suffice, the researchers said
People previously infected with the novel coronavirus respond very strongly to a single dose of the Pfizer-BioNTech COVID-19 vaccine, regardless of when they were infected and whether or not they had detectable antibodies against the disease prior to receiving the preventive, according to a study.
Researchers from Bar-Ilan University and Ziv Medical Center in Israel noted that the real-world evidence with regard to the COVID-19 vaccine remains scarce even though the clinical trial data are encouraging.
Specifically, the response to the COV